Carlos Barbas

Carlos F. Barbas III (5 November 1964 – 24 June 2014) was chair professor of the Janet and Keith Kellogg II and a chemist at the Scripps Research Institute. Barbas developed new therapies that can target HIV-1 and some kinds of cancer which went into clinical trials. In 1989, he finished his PhD in Organic Chemistry under Chi-Huey Wong at the Texas A&M University.

Career From 1981 to 1991, Barbas started postdoctoral studies with Stephen J. Benkovic at the Pennsylvania State University, and began doing research with Richard Lerner at The Scripps Research Institute. In 2008, Zynegenia, a bio-therapeutics company, was founded by Barbas. This time, Barbas dedicated to develop the next generation of drugs with the help of the antibodies invented in his researches.

, Barbas has an h-index of 135 according to Google Scholar and of 112 according to Scopus.

Awards From 1992 to 1995, Barbas won the Scholar of the American Foundation for AIDS Research. Since 2003, Barbas is an ISI Highly Cited Research. In 2009, Barbas has been honored with numerous awards. New York Times reported that, "He was the recipient of the Investigator Award from the Cancer Research Institute, the Presidential Green Chemistry Challenge Award, Arthur C. Cope Scholar Award from the American Chemical Society, a National Institutes of Health (NIH) Director's Pioneer Award and the Tetrahedron Young Investigator Award in Bio-organic and Medicinal Chemistry." In 2014, He gain the scholar of The American Foundation for AIDS Research and was elected a member of both the American Association for the Advancement of Science and the Academy of Microbiology.

Death Barbas was diagnosed with medullary thyroid cancer and died on June 24, 2014.